FDA Approves Single REMS for Mycophenolate Class of Drugs

Article

FDA approved a single shared Risk Evaluation and Mitigation Strategy (REMS) for all mycophenolate-containing prescription drugs at the end of September.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.